Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185783 · ClinicalTrials.gov registry record
Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis
A clinical trial of Sepsis and Relative Adrenal Insufficiency, sponsored by Stanford University.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00185783 is a study of Sepsis and Relative Adrenal Insufficiency that has completed, run by Stanford University. The registered enrollment target is 10 participants, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00185783, a study of Sepsis and Relative Adrenal Insufficiency, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to (1) examine the changes in gene expression in patients who suffer from severe sepsis and whose shock (inadequate oxygen delivery to vital organs) state does not respond to fluid and vasopressor administration, (2) to show that our sampling method of isolating RNA provides reliable and consistent data, (3) provide a basis for future gene expression studies in critically ill patients
Conditions Studied
Interventions
- DRUG Hydrocortisone Administration (Standard of Care Therapy)
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185783
The ClinicalTrials.gov registry entry for NCT00185783 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Hydrocortisone Administration (Standard of Care Therapy) is the first listed.
NCT00185783 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00185783 about?
NCT00185783 is a clinical study titled "Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis". The purpose of this pilot study is to (1) examine the changes in gene expression in patients who suffer from severe sepsis and whose shock (inadequate oxygen delivery to vital organs) state does not respond to fluid and vasopressor administration, (2) to show that our sampling method of isolating RN...
What is the current status of trial NCT00185783?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2005-03. Estimated completion is 2006-11.
What conditions does trial NCT00185783 study?
This clinical trial studies the following conditions: Sepsis, Relative Adrenal Insufficiency.
What interventions are being tested in trial NCT00185783?
The interventions under investigation include: Hydrocortisone Administration (Standard of Care Therapy) (DRUG).
Who is sponsoring clinical trial NCT00185783?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185783 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.